130 related articles for article (PubMed ID: 2208039)
1. Neuropeptide Y and neuron-specific enolase levels in benign and malignant pheochromocytomas.
Grouzmann E; Gicquel C; Plouin PF; Schlumberger M; Comoy E; Bohuon C
Cancer; 1990 Oct; 66(8):1833-5. PubMed ID: 2208039
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum neuron-specific enolase in patients with malignant pheochromocytoma.
Oishi S; Sato T
Cancer; 1988 Mar; 61(6):1167-70. PubMed ID: 3342373
[TBL] [Abstract][Full Text] [Related]
3. [Bilateral adrenal pheochromocytoma. Diagnosis and follow-up using the clonidine test and measurement of plasma neuropeptide Y concentration].
Eisenhut S; Rascher W; Lang RE
Monatsschr Kinderheilkd; 1990 Sep; 138(9):631-4. PubMed ID: 2233767
[TBL] [Abstract][Full Text] [Related]
4. [A case of malignant pheochromocytoma with high levels of serum neuron-specific enolase (NSE) and calcitonin].
Ikeda I; Okuno T; Terao T; Masuda M; Hirokawa M
Hinyokika Kiyo; 1994 Sep; 40(9):813-6. PubMed ID: 7801842
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptide Y as a plasma marker for phaeochromocytoma, ganglioneuroblastoma and neuroblastoma.
Mouri T; Sone M; Takahashi K; Itoi K; Totsune K; Hayashi Y; Hasegawa S; Ohneda M; Murakami O; Miura Y
Clin Sci (Lond); 1992 Aug; 83(2):205-11. PubMed ID: 1327637
[TBL] [Abstract][Full Text] [Related]
6. Neuropeptide Y in multiple endocrine neoplasia: release during surgery for phaeochromocytoma.
Connell JM; Corder R; Asbury J; Macpherson S; Inglis GC; Lowry P; Burt AD; Semple PF
Clin Endocrinol (Oxf); 1987 Jan; 26(1):75-84. PubMed ID: 2879655
[TBL] [Abstract][Full Text] [Related]
7. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma.
deS Senanayake P; Denker J; Bravo EL; Graham RM
J Clin Invest; 1995 Nov; 96(5):2503-9. PubMed ID: 7593641
[TBL] [Abstract][Full Text] [Related]
8. Release of neuropeptide Y and hemodynamic changes during surgical removal of human pheochromocytomas.
Eurin J; Barthélemy C; Masson F; Maistre G; Soualmia H; Noé E; Sarfati E; Eurin B; Carayon A
Regul Pept; 2000 Jan; 86(1-3):95-102. PubMed ID: 10672908
[TBL] [Abstract][Full Text] [Related]
9. Does plasma neuropeptide-Y immunoreactivity in patients with pheochromocytoma depend on hormonal activity of the tumor?
Pruszczyk P; Wocial B; Ignatowska-Switalska H; Feltynowski T; Ellafi M; Januszewicz A; Lapiński M; Zukowska-Grojec Z; Januszewicz W
Clin Chim Acta; 1995 Dec; 243(2):205-12. PubMed ID: 8747495
[No Abstract] [Full Text] [Related]
10. Plasma neuropeptide Y concentrations in patients with neuroendocrine tumors.
Grouzmann E; Comoy E; Bohuon C
J Clin Endocrinol Metab; 1989 Apr; 68(4):808-13. PubMed ID: 2466046
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of neuropeptide Y immunoreactivity in patients with pheochromocytoma: influence on the diagnostic power of measuring plasma NPY using antisera with different specificities.
Tabarin A; Cassiède P; Minot AP; Cuber JC; Roger P; Ducassou D
Acta Endocrinol (Copenh); 1993 Mar; 128(3):243-50. PubMed ID: 8480474
[TBL] [Abstract][Full Text] [Related]
12. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma.
Helman LJ; Cohen PS; Averbuch SD; Cooper MJ; Keiser HR; Israel MA
J Clin Oncol; 1989 Nov; 7(11):1720-5. PubMed ID: 2809684
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunoassay of neuropeptide Y (NPY) in biological fluids. Circulating NPY levels depend on renal function.
Stridsberg M; Lundqvist G
Clin Chim Acta; 1989 Oct; 185(1):61-71. PubMed ID: 2620455
[TBL] [Abstract][Full Text] [Related]
14. Plasma neuropeptide Y immunoreactivity influences left ventricular mass in pheochromocytoma.
Kuch-Wocial A; Slubowska K; Kostrubiec M; Pasierski T; Januszewicz W; Switalska H; Wocial B; Pruszczyk P
Clin Chim Acta; 2004 Jul; 345(1-2):43-7. PubMed ID: 15193976
[TBL] [Abstract][Full Text] [Related]
15. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
16. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
[TBL] [Abstract][Full Text] [Related]
17. Increased plasma immunoreactive neuropeptide Y concentrations in phaeochromocytoma and chronic renal failure.
Takahashi K; Mouri T; Itoi K; Sone M; Ohneda M; Murakami O; Nozuki M; Tachibana Y; Yoshinaga K
J Hypertens; 1987 Dec; 5(6):749-53. PubMed ID: 3429875
[TBL] [Abstract][Full Text] [Related]
18. Plasma concentration of neuropeptide Y in patients with adrenal hypertension.
Tabarin A; Minot AP; Dallochio M; Roger P; Ducassou D
Regul Pept; 1992 Nov; 42(1-2):51-61. PubMed ID: 1475406
[TBL] [Abstract][Full Text] [Related]
19. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment.
Rao F; Keiser HR; O'Connor DT
Hypertension; 2000 Dec; 36(6):1045-52. PubMed ID: 11116123
[TBL] [Abstract][Full Text] [Related]
20. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases.
Schlumberger M; Gicquel C; Lumbroso J; Tenenbaum F; Comoy E; Bosq J; Fonseca E; Ghillani PP; Aubert B; Travagli JP
J Endocrinol Invest; 1992 Oct; 15(9):631-42. PubMed ID: 1479146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
